Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Vyne Therapeutics Inc. (VYNE) since 2018 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Vyne Therapeutics Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1566044.
Total stock buying since 2018: $31,747,034.
Total stock sales since 2018: $9,145,740.
Total stock option exercises since 2018: $342,312.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 15,000 | $43,800 | 0 | $0 | 0 | $0 |
| 2023 | 43,000 | $125,458 | 0 | $0 | 0 | $0 |
| 2021 | 4,256,909 | $10,125,261 | 1,838,897 | $5,320,740 | 0 | $0 |
| 2020 | 2,867,702 | $5,247,503 | 0 | $0 | 75,000 | $111,000 |
| 2019 | 0 | $0 | 0 | $0 | 437,490 | $231,312 |
| 2018 | 953,236 | $16,205,012 | 500,000 | $3,825,000 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-01 | 15,000 | $43,800 | 0 | $0 | 0 | $0 |
| 2023-11 | 13,000 | $50,778 | 0 | $0 | 0 | $0 |
| 2023-03 | 30,000 | $74,680 | 0 | $0 | 0 | $0 |
| 2021-11 | 12,500 | $12,700 | 0 | $0 | 0 | $0 |
| 2021-08 | 12,500 | $20,000 | 838,897 | $1,650,740 | 0 | $0 |
| 2021-05 | 0 | $0 | 1,000,000 | $3,670,000 | 0 | $0 |
| 2021-03 | 12,500 | $92,562 | 0 | $0 | 0 | $0 |
| 2021-01 | 4,219,409 | $9,999,999 | 0 | $0 | 0 | $0 |
| 2020-12 | 50,000 | $85,450 | 0 | $0 | 0 | $0 |
| 2020-09 | 115,000 | $162,055 | 0 | $0 | 0 | $0 |
| 2020-08 | 0 | $0 | 0 | $0 | 75,000 | $111,000 |
| 2020-06 | 2,702,702 | $4,999,998 | 0 | $0 | 0 | $0 |
| 2019-12 | 0 | $0 | 0 | $0 | 437,490 | $231,312 |
| 2018-07 | 0 | $0 | 500,000 | $3,825,000 | 0 | $0 |
| 2018-01 | 953,236 | $16,205,012 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-01-15 | Lepore Patrick G | Buy | 15,000 | 2.92 | 43,800 |
| 2023-11-15 | Lepore Patrick G (Director) | Buy | 13,000 | 3.91 | 50,778 |
| 2023-03-20 | Harsch Mutya (Chief Legal Officer and GC) | Buy | 10,000 | 2.50 | 25,000 |
| 2023-03-20 | Lepore Patrick G (Director) | Buy | 20,000 | 2.48 | 49,680 |
| 2021-11-30 | Lepore Patrick G (Director) | Buy | 12,500 | 1.02 | 12,700 |
| 2021-08-25 | Lepore Patrick G (Director) | Buy | 12,500 | 1.60 | 20,000 |
| 2021-08-16 | Edelman Joseph (10% Owner) | Sale | 250,000 | 1.74 | 435,000 |
| 2021-08-13 | Edelman Joseph (10% Owner) | Sale | 250,000 | 1.84 | 460,000 |
| 2021-08-12 | Edelman Joseph (10% Owner) | Sale | 338,897 | 2.23 | 755,740 |
| 2021-05-06 | Edelman Joseph (10% Owner) | Sale | 1,000,000 | 3.67 | 3,670,000 |
| 2021-03-15 | Lepore Patrick G (Director) | Buy | 12,500 | 7.41 | 92,562 |
| 2021-01-28 | Edelman Joseph (10% Owner) | Buy | 4,219,409 | 2.37 | 9,999,999 |
| 2020-12-03 | Lepore Patrick G (Director) | Buy | 50,000 | 1.71 | 85,450 |
| 2020-09-08 | Domzalski David (President and CEO) | Buy | 75,000 | 1.38 | 103,575 |
| 2020-09-08 | Saik Andrew (Chief Financial Officer) | Buy | 40,000 | 1.46 | 58,480 |
| 2020-08-20 | Barbari Sharon (Director) | Option Ex | 75,000 | 1.48 | 111,000 |
| 2020-06-09 | Edelman Joseph (Director) | Buy | 2,702,702 | 1.85 | 4,999,998 |
| 2019-12-11 | Kwon Paul (Chief Scientific Officer) | Option Ex | 80,300 | .00 | 0 |
| 2019-12-11 | Krasnow Ronald A. (See Remarks) | Option Ex | 24,090 | .00 | 0 |
| 2019-12-11 | Basta Steven L (Chief Executive Officer) | Option Ex | 252,800 | .92 | 231,312 |
| 2019-12-11 | Ball Kristine M (See Remarks) | Option Ex | 80,300 | .00 | 0 |
| 2018-07-24 | Sohail Faysal A. | Sale | 500,000 | 7.65 | 3,825,000 |
| 2018-01-25 | Venbio Global Strategic Fund Ii L.p. (10% Owner) | Buy | 265,000 | 17.00 | 4,505,000 |
| 2018-01-25 | Remeditex Ventures Llc (10% Owner) | Buy | 100,000 | 17.00 | 1,700,000 |
| 2018-01-25 | Vivo Capital Fund Viii, L.p. (10% Owner) | Buy | 294,118 | 17.00 | 5,000,006 |
| 2018-01-25 | Cha Albert (Director) | Buy | 294,118 | 17.00 | 5,000,006 |
Insider trading activities including stock purchases, stock sales, and option exercises of VYNE listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Vyne Therapeutics Inc. (symbol VYNE, CIK number 1566044) see the Securities and Exchange Commission (SEC) website.